. Author manuscript; available in PMC: 2014 Jun 1.

Published in final edited form as: Aliment Pharmacol Ther. 2013 Apr 10;37(11):1103–1111. doi: 10.1111/apt.12304

Table 2.

Comparison between CFU concentrations in patients with dysmotility and PPI use among groups

CFU	Factor	Overall group n =150	SIBO n =38 (25.3%)	SIFO n =24 (16%)	SIBO &SIFO n =32 (21.3%)	No Overgrowth n =56 (37.3%)
10³	Dysmotility	Yes (n=80)	23 (60.5%) ^*	13 (54.2%) ^*	25 (78.1%) ^*	19 (33.9%)
	Dysmotility	No (n=70)	15 (39.5%)	11 (45.8%)	7 (21.9%)	37 (66.1%)

	PPI use	Yes (n=65)	21 (55.3%) ^*	11 (45.8%) ^*	17 (53.1%) ^*	16 (28.6%)
	PPI use	No (n=85)	17 (44.7%)	13 (54.2%)	15 (46.9%)	40 (71.4%)

		Overall group n =150	SIBO n =20 (13.3%)	SIFO n =40 (26.6%)	SIBO &SIFO n =16 (10.6%)	No Overgrowth n =73 (48.6%)

10⁵	Dysmotility	Yes (n=80)	12 (60.5%)	22 (55%)	14 (88%) ^*	29 (39.7%)
	Dysmotility	No (n=70)	8(39.5%)	18 (45%)	2 (12%)	44 (60.3%)

	PPI use	Yes (n=65)	10 (50%)	21 (52.5%) ^*	10 (63%) ^*	25 (34%)
	PPI use	No (n=85)	10 (50%)	19 (47.5%)	6 (47%)	54 (66%)

= < 0.05 versus no overgrowth group